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Introduction
The respiratory tract is a widely branched sys-
tem of ducts, which start from the nostrils (from the
mouth in the case of mouth breathing) and include:
the nasal cavities, the pharynx and larynx up to the
lower edge of the cricoid cartilage (upper airways),
the trachea and the various orders of bronchi to the
terminal bronchioles (lower airways). Going
through these ducts, the inhaled air is changed and
conveyed to the alveolar structures, home of the
respiratory exchange with the blood.
They are therefore particularly exposed to the
action of pathogenic microorganisms transmitted by
air and not surprisingly the high frequency of infec-
tions they face especially in the first years of life;
respiratory tract infections in fact represent the 50%
of all diseases in pre-school children and 30% of
those between 5 and 12 years. Moreover it is wide-
ly-documented how in the first three years of life all
children without statistically difference among sex,
experience at least eight episodes of respiratory
infections per year, a rate that decreases then to six
in the range of age between 3 and 7(1, 2).
Commonly it is usual to distinguish: upper res-
piratory tract infections (URTI) from lower respira-
tory tract infections (LRTI). The pathogens
involved are basically the same, considered the
anatomical and physiological commonality between
upper and lower respiratory tracts deriving from the
common embryological origin (subsequent bud-
dings of the primitive foregut endodermal tube
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ABSTRACT
Respiratory tract infections are the most common diseases in childhood. The respiratory tract, widely branched system of
ducts, is particularly exposed to the action of microorganisms transmitted by air from here the high frequency of infections they face
especially in the first years of life. It is usual distinguish: upper respiratory tract infections (URTI) and lower respiratory tract infec-
tions (LRTI). In particular, in infections of the upper airways, the inflammatory process, result of the interaction between microbes
and the immune response, can be localized to the mucosa of the nose or sinuses (common cold and sinusitis), or the pharynx or
larynx (pharyngotonsillitis and laryngitis) and it has predominantly a viral etiology although occasionally it may be followed by bac-
terial complications such as otitis media. The aim of the following article is the description of these different clinical pictures, highli-
ghting the clinical and epidemiological features and current management guidelines.          
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between the second and the fourth bronchial pock-
et). The most frequently viruses responsible for res-
piratory diseases are: the respiratory syncytial virus,
influenza viruses A, B and C, and the parainfluenza,
adenoviruses, rhinoviruses and enteroviruses occa-
sionally in the summer months (both belonging to
the family of picornaviruses), coronavirus and the
newly identify bocavirus(3). To these viruses proper
we must add some mycoplasmas and bacteria (such
as Streptococcus pneumoniae, Haemophilus
influenzae, Staphylococcus aureus,  Moraxella
catarrhalis, and others)(4, 5, 6).
The inflammatory process always occurs with
the same features: inflammation and edema of the
mucosa, vascular congestion, hypersecretion of
mucus and alteration of transport and mucus ciliary
clearance.
From what has been affirmed it can be stated
that different infectious agents are responsible for
respiratory ailments like and therefore one of the
most effective criteria to define them results to be
the  anatomy clinical localization of the infection,
from the nose to the lung parenchyma. 
In particular, in infections of the upper airway,
the inflammatory process, result of the interaction
between microbes and the immune response(7), can
be localized to the mucosa of the nose or sinuses, or
the pharynx or larynx, and it has predominantly a
viral etiology although occasionally it may be fol-
lowed by bacterial complications such as sinusitis
and otitis media. We can distinguish in this way,
according to the prevailing location and the intensi-
ty of symptoms, different clinical pictures such as
the common cold or rhinitis, the sinusitis and the
rhinosinusitis, the pharyngotonsillitis, laryngitis and
finally the otitis media.
Materials and methods
The author’s search targeted evidence-based
guidelines, evidence-based summaries, systematic
reviews, and controlled trials of interventions for
rhinosinusitis, pharyngitis, and otitis media. 
The keywords used were ‘‘rhinitis’’ or ‘‘com-
mon cold’’ or ‘‘rhinosinusitis’’ or ‘‘pharyngitis’’ or
‘‘tonsillitis’’ or ‘‘otitis’’ and (practice guideline or
systematic or clinical evidence or clinical trial).  
Even this simple strategy identified more than
6500 sources using PubMed alone. Inclusion as an
evidence-based guideline, summary, or systematic
review required an explicit search strategy and cri-
teria for study inclusion.
Inclusion as a clinical trial required random-
ization. The author used three primary sources to
identify relevant information: Clinical Evidence
(http://clinicalevidence.bmj.com); the Cochrane
library (http://www3.interscience.wiley.com/cgi-
bin/mrwhome/106568753/HOME); Medline and
SCOPUS (last accessed via PubMed and SCOPUS
on October 16, 2014).
Discussion
Common cold or rhinitis
Among the diseases of the upper respiratory
tract during the winter and spring, which make up
50% of all diseases in pre-school children and 30%
of those between 5 and 12 years, rhinitis or com-
mon cold is undoubtedly the most frequent(4). 
This inflammatory process of the nasal
mucosa in most cases tends to heal spontaneously.
The symptoms (stuffy nose, sneezing, runny nose,
and in more severe infections fever, illness, and
muscle aches) usually resolve within a few days,
but may persist for up to one to two weeks. The
pathogens responsible are for 90% viral agents (rhi-
novirus, adenovirus, respiratory syncitial virus,
influenza and parainfluenza virus) and only occa-
sionally bacterial pathogens Streptococcus pneumo-
niae, Haemophilus influenzae and Moraxella
catarrhalis)(7).
The treatment is mainly symptomatic and con-
sidering the prevailing viral nature of affection,
administration of antibiotics is not recommended
by the main guidelines(6). Among the drugs parac-
etamol is the most employed (it is the drug of first
choice in paediatrics, after more than 40 years of
use), used as antipyretic and analgesic, with few
side effects (liver and renal toxicity), mostly related
to overdose(8,9,10). To relieve nasal congestion and
restore normal mucosa, especially in infancy and
early childhood, with topical nasal decongestants
are preferred nasal washes with saline or hypertonic
saline, to be carried out several times during the
day. These washes remove secretions, moisturize
and relieve congestion of the mucous membranes,
facilitate the elimination of airborne particles such
as allergens and dust environment and foster the
reactivation of mucociliary clearance(11, 12). For all
these reasons, they are not only indicated in the
treatment and prevention of colds but also in other
related diseases such as sinusitis, otitis and pharyn-
golaryngitis as well as in allergies(13, 14). 
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Rhinosinusitis
When the inflammation in the nasal mucosa
lasts for more than ten days and/or is particularly
intense, the edema which results may determine,
with the interaction of predisposing factors, the
obstruction of one or more of the hosts that physio-
logically ensure the normal drainage of the
paranasal sinuses. The obstruction, which could be
origin of the onset of migraine(15), leads to the for-
mation of a closed sinus space, separated from the
corresponding nasal cavity and characterized by a
decrease in oxygen tension and endosinusal pH, cil-
iary dysfunction and stagnation of secretions, con-
ditions that favour the engraftment and proliferation
of pathogenic bacteria(16).
A simple rhinitis, usually of viral origin, thus
evolving into a more serious bacterial infection of
the nose and paranasal sinuses for which we talk
about rhinosinusitis, reserving the terms of rhinitis
and sinusitis to self limited and short lived infec-
tions. In many individuals, however, rhinitis and
sinusitis are often coexist and for this reason we
prefer the unique term rhinosinusitis(17).
The acute rhinosinusitis has symptoms that
may persist for 10 to 30 days and may occur in mild
form (with nasal obstruction, rhinorrhea catarrhal
moderate facial pain, absent or moderate fever) and
in severe form (with strong nasal congestion,
mucopurulent rhinorrhea, facial pain from moderate
to severe pain, high fever, cough and headache)(15).
The diagnosis is usually based on clinical signs and
nasal endoscopy using optic fibres, reserving the
radiological examinations for children with severe
complicated cases that do not respond to drug ther-
apies(18). These, as recommended by the American
Academy of Otolaryngology Head and Neck
Surgery Foundation, vary according to the severity
of the clinical picture: in mild forms is preferable to
delay antibiotic treatment for a few days and in the
meantime using anti-inflammatory drugs, nasal
decongestants (to be used for limited periods of
time to avoid mucosal abnormalities and possible
rebound effect and complications or systemic infec-
tion) without forgetting the already mentioned nasal
washes with hypertonic saline.
When the symptomatology lasts for more than
15 days, to the treatment already mentioned, should
be associated an antibiotic treatment to ensure heal-
ing, prevent complications and/or chronicity.
According to current guidelines in mild acute rhi-
nosinusitis, bearing in mind that the most responsi-
ble germs are Streptococcus pneumoniae,
Haemophilus influenzae and Moraxella catarrhalis,
the first line antibiotic is oral amoxicillin (50
mg/kg/day in three divided doses for 10 days), con-
sidering its action on these germs. In case of intol-
erance, treatment failure, emergence of resistance
or other different pathogens, according to each
case, it is possible to resort to the association amox-
icillin/clavulanic acid (80-90 mg/kg/day in three
doses) or to a second or third generation
cephalosporin, to a macrolide or, in the case of
allergy, to B-lactam antibiotics. In severe compli-
cated cases you may approach the administration by
injection of ceftriaxone (100 mg/kg/day in a single
dose) or cefotaxime (100 mg/kg/day in three divid-
ed doses) or ampicillin-sulbactam (100-
200mg/kg/day in three doses). In these cases,
antibiotic treatment may vary from 14 to 28 days,
even though the optimal duration of antibiotic ther-
apy in various forms of rhinosinusitis is not well
defined up today(18, 19, 20, 21, 22). 
Pharyngonsillitis and Laryngitis
The pharyngitis and tonsillitis diseases are
very frequent between 4 and 10 years, in these
cases the inflammatory process involves the
oropharynx and/or the tonsils and in the majority of
cases has viral etiology with a clinical outcome
(characterized by sore throat, cough, fever, rhinor-
rhea, general malaise) that resolve within three to
five days with a predominantly symptomatic treat-
ment. However, in 37% of cases of acute pharyngi-
tis the germ responsible results to be B-hemolytic
Streptococcus group A (SBEGA)(23). The streptococ-
cal infection, rare in the first three years of life, is
characterized by the following signs and symptoms:
high fever with sore throat, pharyngeal exudate
and/or tonsils, headache, gastrointestinal symptoms,
anterior cervical lymph edema and increased in vol-
ume, presence of petechiae at the level of the soft
palate. If not treated properly with antibiotics, it can
undergo suppurate complications (cervical lym-
phadenitis, peritonsillar abscess and/or back of
throat, ear infections and sinusitis), and not suppu-
rate as acute rheumatic fever, glomerulonephritis,
and reactive arthritis. Penicillin V (45mg/kg/die in
three doses) is the first line antibiotic according to
the main guidelines, although recent trials have
highlighted a greater effectiveness of amoxicillin
(50mg/kg/die in two divided doses) both used for a
period of at least ten days.
In case of allergies to these molecules you
may resort to the use of macrolides such as clar-
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ithromycin (15mg/kg/die in two doses) for ten days
or azithromycin (10mg/kg/die) for three days(24, 25). 
Even for laryngitis, inflammatory processes of
the larynx, the most common cause are viruses,
although it is not to exclude the presence of bacteri-
al agents when the laryngeal disease is due to a bac-
terial pharyngitis. Considering then the prevalent
viral nature antibiotic treatment is not suitable and
in the presence of more severe forms can be used
an oral anti-inflammatory. What is important, in the
presence of laryngeal affection, is to exclude the
presence of a medical emergency such as epiglotti-
tis for which it is urgent hospitalization to ensure a
regular respiratory tracts functions and initiate
antibiotic therapy with a third-generation
cephalosporin (ceftriaxone or cefotaxime)(26). 
Otitis Media
As reported in literature from 29% to 50% of
URTI evolves in otitis media (OM) (7,27), an
inflammatory process of the middle ear generally
associated to fluid accumulation in the tympanic
cavity (the latter detected by the presence of
swelling, presence of air-fluid levels limited or
absent mobility of the tympanic membrane and/or
otorrhea). In general, there are two forms of otitis
media: an acute (AOM) with rapid onset, character-
ized by signs and symptoms of inflammation of the
middle ear (tympanic membrane erythema, otalgia,
otorrhea, fever, and/or irritability especially in
younger children)(28) associated with effusion, and a
form of otitis media with effusion (OME) in which
there aren’t any signs and symptoms of acute
inflammation. This latter can occur de novo or as a
sequel to an acute form then, the two forms can be
considered different stages of a unique process of
the middle ear(29). The pathogens are mainly respon-
sible, in both cases, Streptococcus pneumoniae,
Haemophilus influenzae and Moraxella
catarrhalis(30, 31). 
In the treatment of AOM the goal is to achieve
the resolution of symptoms and the prevention of
relapse. In children younger than 6 months, the
guidelines of the American Academy of Pediatrics
suggest an attitude of watchful waiting that imme-
diately takes into account pain symptoms with the
possible administration of analgesics (paracetamol,
ibuprofen) and postpones to 48-72 hours treatment
with antibiotics. The Antibiotic therapy is however
indicated in all children younger than 6 months,
those aged between 6 months and two years in
diagnosis and for children older than 2 years with
severe infection (all subjects are at high risk of
experiencing recurrent episodes, and septic compli-
cations in chronic forms.  The drug of first choice is
amoxicillin associated with clavulanic acid to be
administered at intervals of 8 hours, choice shared
by the main international guidelines but do not
agree dosage to be used: 40-45 mg/kg/day (standard
dose) for some, 90 mg/kg/day for others. The dura-
tion of treatment may vary, depending on the sever-
ity of the case and the age of the young patient,
from 5-7 days to 10 days. In patients allergic to
penicillin, the choice may fall on azithromycin or
clarithromycin(31, 32). 
In the case of OME, as a recent study by
Martines and others confirms the literature data, it
is shown how children with a history of upper res-
piratory tract infections (URTI) are more likely to
develop this form of otitis(33,34). Hence the necessity
of observing these young patients integrating with
the medical history and clinical examination with
audiometry and tympanometry to settle a diagnostic
suspicion and establish adequate therapy.
Particularly in the management of these pathologi-
cal conditions it is necessary to achieve two impor-
tant goals: first, to heal the inflammatory process
interesting the upper airway (restoring the ventila-
tion of the 'middle ear through the Eustachian tube
and reducing the bacterial load), and second, pre-
vent new episodes of URTI and OME, maintaining
the normal physiology of the mucosa of the upper
airways and strengthening the immune system,
avoiding middle-ear surgery(7, 34, 35, 36).
Conclusion
URTI can be neutralized with antibiotic thera-
py (limiting the use of aminoglycosides and
macrolides for their ototoxic effect)(37), associated
with the administration of steroids for nasal route (to
reduce eosinophil infiltration) and/or antihistamines
(in particular for allergic forms), all supported by
irrigations nasal saline solutions (to help to release
allergens and mucus from the nose). For the preven-
tion it may be used the administration of bacterial
lysates orally, such as OM-85, a bacterial lysate of
Streptococcus pneumoniae, Haemophilus influenzae
and other bacteria particularly involved in URTI and
otitis media, which is effective in reducing the num-
ber and intensity of infections(31, 38).
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